Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + Idarubicin (SGI5 + Ida), and 5 days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian Design

Guadecitabine is a novel hypomethylating dinucleotide of decitabine and deoxyguanosine resistant to degradation by cytidine deaminase. This allows gradual and prolonged exposure of leukemia cells to its active metabolite, decitabine.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Kiran Naqvi, Garciela Nogueras Gonzalez, Cora Cheung, Naveen Pemmaraju, Elias Jabbour, Guillermo Garcia-Manero, Courtney DiNardo, Maro Ohanian, Nitin Jain, Koichi Takahashi, Yesid Alvarado, Marina Konopleva, Xuelin Huang, Jorge Cortes, Hagop Kantarjian Source Type: research